SLS

SLS

Sellas Life Sciences Group Inc

SELLAS Life Sciences Group develops novel cancer therapeutics, focusing on peptide immunotherapy galinpepimut-S and CDK9 inhibitor SLS009. The company partners with Merck & Co. and others to advance treatment options for various cancer types.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 10 years ago โ†’$1today

Score Overview

1 Year
Scoreโ€”
Net Growth-9.66%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.2
Net Growth-42.31%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-24.01%
Net Trend56%
Net Income Consistency
Rev Growthโ€”
Rev Trend22%
Revenue Consistency

See the full market ranking โ†’

Sellas Life Sciences Group Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 1.9K to $ 0.00 and net income went from -$ 16M to -$ 26M. Revenue increased in 0 of those 5 years; net income in 3.

Sellas Life Sciences Group Inc currently holds a 5-year HDB Score of 3.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 11.77โ€”
1 Year2025-08-12
$ 1.617x
5 Years2021-08-12
$ 9.9118.77%
10 Years2016-08-12
$ 12.66K-99.91%
All Time2017-12-29
$ 393.00-97.01%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 29M$ 107M
2025$ 0.00-$ 26M$ 71M
2024$ 0.00-$ 30M$ 13M
2023$ 0.00-$ 37M$ 2M
2022$ 1M-$ 41M$ 17M
2021$ 7M-$ 20M$ 21M
2020$ 1.9K-$ 16M$ 35M
2019$ 0.00-$ 19M$ 7M
2018$ 0.00-$ 27M$ 5M
IPO2017$ 0.00-$ 23M$ 2M

Explore beyond SLS

You're looking at Sellas Life Sciences Group Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies